Guardant Health Inc (GH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guardant Health Inc (GH) has a cash flow conversion efficiency ratio of 0.142x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.08 Million) by net assets ($-99.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guardant Health Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Guardant Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Guardant Health Inc for a breakdown of total debt and financial obligations.
Guardant Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guardant Health Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REXEL S.A. ADR EO 5
F:E7V0
|
N/A |
|
DraftKings Inc
NASDAQ:DKNG
|
0.508x |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
0.169x |
|
Industrivarden AB ser. A
ST:INDU-A
|
0.048x |
|
Avidity Biosciences, Inc
NASDAQ:RNAM
|
-0.101x |
|
VAT GROUP AG UNSP.ADR 10
F:19V0
|
N/A |
|
Inner Mongolia Xingye Mining Co Ltd
SHE:000426
|
0.112x |
|
China Resources Microelectronics Ltd
SHG:688396
|
0.026x |
Annual Cash Flow Conversion Efficiency for Guardant Health Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Guardant Health Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Guardant Health Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-99.31 Million | $-184.76 Million | 1.860x | +8.32% |
| 2024-12-31 | $-139.65 Million | $-239.86 Million | 1.718x | +183.87% |
| 2023-12-31 | $158.68 Million | $-324.98 Million | -2.048x | +60.17% |
| 2022-12-31 | $60.18 Million | $-309.46 Million | -5.142x | -1486.86% |
| 2021-12-31 | $645.00 Million | $-209.02 Million | -0.324x | -322.69% |
| 2020-12-31 | $1.36 Billion | $-103.93 Million | -0.077x | -37.93% |
| 2019-12-31 | $847.99 Million | $-47.13 Million | -0.056x | +59.58% |
| 2018-12-31 | $524.95 Million | $-72.19 Million | -0.138x | +41.25% |
| 2017-12-31 | $308.61 Million | $-72.23 Million | -0.234x | +49.18% |
| 2016-12-31 | $79.70 Million | $-36.71 Million | -0.461x | -- |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more